The patent relates to the automated isolation of rare, therapeutically critical target cells from blood, bone marrow, leukapheresis product, and other cell sources, while maintaining the viability of the cells under asceptic conditions. This advanced technology is part of Cesca’s proprietary CAR-TXpress™ platform that now integrates multi-component automation steps, including T-cell isolation, purification, culture expansion and washing, and single cassette-based automated -196°C cryopreservation and retrieval. The CAR-TXpress™ system provides a comprehensive and commercially viable, automated cellular manufacturing and control (CMC) solution for the development of CAR-T and CAR-NK therapeutics.

Cesca CEO Chris Xu commented, “This new patent issuance significantly strengthens the intellectual property position surrounding our proprietary automation technology which is core to our best-in-class ThermoGenesis portfolio of cell processing systems […] Traditional cell processing methodologies, including those currently being implemented and used by leading CAR-T developers, are manual and time consuming, presenting significant challenges to the future large-scale commercial feasibility of these revolutionary therapies. In contrast, Cesca’s patented, automated cell processing systems provide greater cell yields and higher consistency in a fraction of the time, making them ideally suited to meet industry needs. The ability to leverage our technology to commercialize the BACS process is a milestone achievement for our company.”

Cesca’s ‘394 patent covers a device and methodology for integrating automated cellular separation and buoyancy-activated cell sorting (BACS) processes. BACS employs microscopic bubbles to isolate a specific cell type from a complex mixture of cells, such as blood. These microbubbles bear antibodies on their surface, enabling them to bind specifically to a single desired target cell type. When coated with microbubbles, the target cells float to the top of the host liquid, while non-target cells sink to the bottom – a process that can be accelerated by centrifugation. Subsequent collection of the floating target cell layer and release of the cells from their microbubbles provides a highly-purified preparation of just the cells of interest, with high recovery efficiency while retaining cell viability. Additionally, the ‘394 patent allows for the automated isolation of cells with low density surface antigens, which was previously a major cellular manufacturing challenge.

“Cesca’s unique CAR-TXpress™ cell processing solution begins with BACS-based cell isolation technology to provide the ultra-high levels of cell purity, recovery, and viability of target immune cells from donor blood that therapeutic cell manufacturers increasingly demand,” said Philip Coelho, chief technology officer of ThermoGenesis and co-inventor of the ‘394 patent. “Unlike conventional cell isolation technologies that work on narrow streams of slowly moving suspended cells, our BACS-enabling technology works in bulk volumes of cells, dramatically reducing processing time. With these advantages, we look forward to partnering with leading CAR-T developers as they strive to bring these groundbreaking therapies to patients suffering from cancer and other serious diseases.”

On the ratings front, Maxim analyst Jason Kolbert reiterated a Hold rating on KOOL, in a report issued on May 12. According to TipRanks.com, Kolbert has a yearly average loss of 12.4%, a 31% success rate, and is ranked #4090 out of 4160 analysts.

Cesca Therapeutics, Inc. engages in the research, development, and commercialization of autologous cell-based therapeutics for use in regenerative medicine. Its products include cellular bioprocess technologies, autoexpress (AXP), sterile manual systems, and bioarchive cryostorage.